A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B
2011
Brazilian Journal of Infectious Diseases
and aim: Chronic hepatitis B is a highly prevalent disease worldwide, leading to serious consequences if not properly treated. Six treatment options for chronic hepatitis B are currently provided by the Brazilian public health system. Telbivudine is a nucleoside analogue that is neither included in the Brazilian clinical protocol nor in the therapeutic guidelines for chronic hepatitis B. Objective: The aim of this study was to evaluate the cost-effectiveness of telbivudine for the viewpoint of
doi:10.1016/s1413-8670(11)70180-5
pmid:21670922
fatcat:vpidikkbezcm5drt6gy43jy2na